University Hospital Basel treats coronavirus patients with plasma
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.
Blood cells (img: geralt/Pixabay)
According to a press release from the University Hospital Basel, the plasma that was administered to two Covid-19 patients contains “above all proteins such as coagulation factors and immunoglobulins (antibodies against pathogens).” Since this was the plasma from a patient who had recovered from Covid-19, the plasma also contains proteins that protect against this specific virus. This method has already proven successful against Ebola and swine flu. However, it remains to be seen whether this will be the case with coronavirus as well.
Andreas Buser, Head of the Basel Blood Donation Center, is quoted in an article by SRF, saying: “We have just treated a handful of patients in this way. Only a study will be able to demonstrate whether this treatment actually works.” Together with Manuel Battegay, Chief Physician of Infectiology at the University Hospital Basel, Buser heads up a research group conducting the potential treatment. This group will now follow developments. The hope is that this will be able to decrease the severity and duration of the illness. Battegay tells SRF: “We are currently collecting the initial experience.”
Giving blood is voluntary for patients who have been proven to have recovered from the virus. The University Hospital Basel states that donors are tested for diseases that can be transmitted by blood, and after donating “a range of viruses, bacteria and parasites as well as potentially harmful white blood cells” are neutralized. The recipient is then given the plasma by transfusion via the veins.
Share this article
You might also be interested in
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More
Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation and enterprise campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.Read More
Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.Read More
The American health authority has granted Polyneuron’s drug PN-1007 orphan designation. This status uses special conditions to balance out commercial disadvantages when developing drugs for rare diseases.Read More